42nd week of 2017 patent applcation highlights part 9 |
Patent application number | Title | Published |
20170296517 | INHALABLE AZTREONAM FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS - A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by | 2017-10-19 |
20170296518 | METHOD FOR DIAGNOSING, PREVENTING, AND TREATING NEUROLOGICAL DISEASES - The invention provides for methods of treating autism associated with | 2017-10-19 |
20170296519 | METHODS OF SEDATION DURING CRITICAL CARE TREATMENT - Methods of sedating a patient undergoing critical care treatment using intravenous gaboxadol are provided. | 2017-10-19 |
20170296520 | ADMINISTRATION OF BERBERINE METABOLITES - In various implementations, berberine metabolites, such as dihydroberberine and/or tetrahydroberberine, may be administered to manage blood glucose levels, increase ketone levels (e.g., blood concentration of ketones), and/or for therapeutic purposes in humans. The administration of a pharmaceutically effective amount of berberine metabolites, such as dihydroberberine, may reduce fasting blood glucose levels, improve glucose tolerance, and/or improve blood ketone response. In some implementations, berberine metabolites may be administered with one or more other compounds. | 2017-10-19 |
20170296521 | PHARMACEUTICAL COMPOSITION FOR SUPPRESSION OF THROMBOEMBOLISM AFTER STENT PLACEMENT - It is intended to provide a novel pharmaceutical composition that can suppress thromboembolism after stent placement. The present invention provides a pharmaceutical composition for the suppression of thromboembolism after stent placement, comprising edoxaban or a pharmaceutically acceptable salt thereof, or a hydrate of the compound or the salt. | 2017-10-19 |
20170296522 | STABLE NIMODIPINE PARENTERAL FORMULATION - A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80. | 2017-10-19 |
20170296523 | Pharmaceutical Compositions Comprising Alpelisib - The present invention relates to dispersible tablets comprising the compound (S)-Pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) or a pharmaceutically acceptable salt thereof. | 2017-10-19 |
20170296524 | Method for Assessing the Efficacy of IMIDS and Composition or Combination for Use in Treating IMID Sensitive Diseases - The invention relates to a combination of an immunomodulatory imide drug (IMiD) and an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a subject. It further relates to an inhibitor of CD147 and/or an inhibitor of MCT1 for use in treating a disease in a patient, wherein the patient is IMiD resistant. It further relates to a method of monitoring the efficacy of an IMiD treatment regimen by comparing the protein level of CD147 and/or MCT1 in samples obtained from a subject prior and during IMiD treatment. | 2017-10-19 |
20170296525 | USE OF COTININE IN TREATING OR PREVENTING NEUROGENESIS DEFICITS AND ENHANCING NEUROGENESIS - A method of inhibiting or treating chemotherapy-induced cognitive dysfunction comprising administering a therapeutically effective amount of cotinine to a cancer patient experiencing chemotherapy-induced cognitive dysfunction. | 2017-10-19 |
20170296526 | MEDICAL TREATMENTS BASED ON ANAMORELIN - Methods of treating cancer related conditions using anamorelin are described. | 2017-10-19 |
20170296527 | STABLE NIMODIPINE PARENTERAL FORMULATION - A nimodipine injection concentrate and diluted formulation comprises nimodipine (base or salt), an effective amount of a hydrophilic surfactant, and a pharmaceutically acceptable carrier for injection which is an aqueous solution, an organic solvent, an oil, or a cyclodextrin, such that the nimodipine is substantially contained in a concentrated injection solution, suspension, emulsion or complex as a micelle or a colloidal particle or an inclusion complex and the formulation is stable and clear. In certain embodiments, the hydrophilic surfactant is polysorbate 80. | 2017-10-19 |
20170296528 | Methods of Managing Conditioned Fear with Neurokinin Receptor Antagonists - This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder. In certain embodiments, the neurokinin 3 receptor antagonist is (R)—N-{{3-[1-Benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]prop-1-yl}-4-phenylpiperidin-4-yl}-N-methylacetamine or salts thereof. | 2017-10-19 |
20170296529 | Phosphatidylinositol 3-Kinase Inhibitors for the Treatment of Lymphoproliferative Malignancies - Methods are provided for treating a lymphoproliferative malignancy to a patient in need of such treatment, comprising administering to the patient an effective amount of compound A as described herein. | 2017-10-19 |
20170296530 | Compositions and Methods for Treating and Inhibiting Viral Infections - Compositions and methods for the treatment, as well as the inhibition and prevention, of an infection of the papillomavirus and the epithelial lesions, namely, the warts of the skin and mucosal surfaces, associated therewith, in a mammalian host, as well as methods of inhibiting the replication of a papillomavirus in an infected cell, are provided. The compositions comprise a therapeutically effective amount of an active ingredient comprising at least one compound selected from the group consisting of chloroquine, hydroxychloroquine, amodiaquine, or in each case, a pharmaceutically acceptable salt thereof. The methods comprise topically administering a therapeutically and/or antivirally effective amount of such a compound to a mammalian host, such as a human being, in need of such treatment, although alternatively other routes of administration may be used, including but not limited to transdermal, transmucosal, respiratory, and by injection. The compositions optionally also comprise one or more pharmaceutically acceptable non-active ingredients. | 2017-10-19 |
20170296531 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein. | 2017-10-19 |
20170296533 | Pharmaceutical Formulation Containing Gelling Agent - Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient. | 2017-10-19 |
20170296534 | USE OF LEVOCETIRIZINE AND MONTELUKAST IN THE TREATMENT OF AUTOIMMUNE DISORDERS - The embodiments described herein include methods and formulations for treating autoimmune disorders. The methods and formulations include, but are not limited to, methods and formulations for delivering effective concentrations of levocetirizine and montelukast to a patient in need. The methods and formulations can comprise conventional and/or modified-release elements, providing for drug delivery to the patient. | 2017-10-19 |
20170296535 | METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING ERYTHEMA - Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and a pharmaceutically acceptable carrier. | 2017-10-19 |
20170296536 | OPHTHALMIC SUSPENSION FORMULATION - The present invention relates to a stable ophthalmic suspension formulation comprising (R)-(−)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4-spiro-3′-pyrrolidine-1,2′,3,5′-tetrone, which is useful for treating a disease in posterior eye segment and the like, avoiding side-effects due to systemic exposure. | 2017-10-19 |
20170296537 | AZABICYCLO DERIVATIVES, PROCESS FOR PREPARATION THEROF AND MEDICAL USE THEREOF - Azabicyclo derivatives, a preparation process, and medical use thereof are provided. In particular, azabicyclo derivatives of formula (I), pharmaceutically acceptable salts, stereoisomers, solvates and prodrugs thereof are described. The azabicyclo derivatives of formula (I) are useful as Epidermal Growth Factor Receptor (EGFR) inhibitors. The definitions of the variable R groups in the azabicyclo derviatives of formula (I) are described in the specification. | 2017-10-19 |
20170296538 | SOLUTE AND SOLUTE MIXTURE, AS WELL AS A COMPOSITION COMPRISING AT LEAST ONE SOLUTE, FOR USE IN THE PREVENTION OR TREATMENT OF COSMETIC OR PATHOLOGIC EFFLORESCENCES CAUSED BY AIRBORNE PARTICLES - The invention relates to a compatible solute or a solute mixture, as well as to a composition comprising the solute or solute mixture, for use in the prevention or treatment of cosmetic or pathologic efflorescences caused by airborne particles, such as pigmentation accompanying with skin ageing, and de- or hypopigmentation, hyperpigmentation, as well as alterations accompanying with atrophy in the broadest sense. The solute or solute mixture, as well as the composition comprising the solute or solute mixture comprises at least one compound according to formula I, formula II, physiologically compatible salts of formula I and formula II, stereoisomeric forms of the compound of formula I, formula II, and physiologically compatible salts of the stereoisomeric forms, and the solute mixture comprises at least two of the afore-mentioned compounds, wherein in formula I | 2017-10-19 |
20170296539 | COMPOSITE PREPARATION, CONTAINING NOVEL 3-(4--(BENZYLOXY)PHENYL)HEX-4-INOIC ACID DERIVATIVE AND ANOTHER ACTIVE INGREDIENT, FOR PREVENTING OR TREATING METABOLIC DISEASES - The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases, in which a novel 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative and at least another active ingredient, which is selected from the group consisting of dipeptidyl peptidase-4 (DPPIV) inhibitor-based, sulfonylurea-based, thiazolidinedione (TZD)-based, biguanide-based, and sodium/glucose cotransporter 2 (SGLT2) inhibitor-based drugs, may be administered in combination or in the form of a composite preparation. The use of the composition of the present invention can provide a remarkably excellent blood sugar reducing effect in various animal diabetic disease models, and the composition of the present invention can be favorably used as a pharmaceutical composition for preventing or treating metabolic diseases, such as obesity, diabetes type I, diabetes type II, glucose intolerance symptoms, insulin resistance symptoms, hyperglycemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, and syndrome X. | 2017-10-19 |
20170296540 | METHODS OF TREATING FRIEDREICH'S ATAXIA USING SRC INHIBITORS - In one aspect, the invention presents a method of treating Friedreich's ataxia (FRDA) by administering a therapeutically effective amount of an Src inhibitor. | 2017-10-19 |
20170296541 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING WITH EGFR INHIBITORS - The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with EGFR inhibitor agents. | 2017-10-19 |
20170296542 | COMBINATIONS FOR THE TREATMENT OF NEOPLASMS USING QUIESCENT CELL TARGETING AND INHIBITORS OF MITOSIS - The present invention provides compositions and methods for the treatment of neoplasms, in particular, by targeting of quiescent cancer cells with therapeutic agents in combination with other treatments effective against certain neoplastic conditions, in particular, anti-cancer treatment with therapeutic agents that are inhibitors of mitosis (a mitotic inhibitor). | 2017-10-19 |
20170296543 | SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING BIOPTERIN DERIVATIVES AND USES OF SUCH COMPOSITIONS - The present invention relates to a method of treating a disease in a subject, comprising administering to a subject in need thereof a solid pharmaceutical composition biopterin derivatives. | 2017-10-19 |
20170296544 | LIQUID FORMULATIONS OF (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRI- MIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE - A liquid formulation of (S)—N-(5-((R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide, pharmaceutically acceptable salts thereof, or a combination thereof and the use of the liquid formulation in the treatment of pain, cancer, inflammation, and certain infectious diseases are disclosed. | 2017-10-19 |
20170296545 | Composition Of A Ceramic Matrix With A Controlled Release Drug, A Tablet Obtained From The Composition And Methods For Obtaining The Composition And The Tablet - A composition of a ceramic matrix is defined by pseudoboehmite nanoparticles and is constructed for carrying and releasing medications in a controlled manner, in the treatment of human beings and animals presenting an organic deficiency which requires the application of said medications. A method for preparing said composition, in the form of a ceramic matrix, and also a method of incorporating the drug acyclovir to said ceramic matrix, forms a tablet. | 2017-10-19 |
20170296546 | SUBSTITUTED AMINOPURINE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are Aminopurine Compounds having the following structures: | 2017-10-19 |
20170296547 | DERMOCOSMETIC OR PHARMACEUTICAL USE OF A COMPOSITION COMPRISING AT LEAST ONE INHIBITOR OF SOME CHEMOATTRACTANT CYTOKINES - The present invention relates to the cosmetic or pharmaceutical use for a composition comprising a salicylic or nicotinic acid derivative inhibiting chemokines, for preventing or treating chronic internal and/or external inflammatory conditions. | 2017-10-19 |
20170296548 | DERIVATIVES OF 6-SUBSTITUTED TRIAZOLOPYRIDAZINES AS REV-ERB AGONISTS - The present invention provides novel 6-substituted [1,2,4]triazolo[4,3-b]pyridazines that are agonists of Rev-Erb. These compounds, and pharmaceutical compositions comprising the same, are suitable means for treating any disease wherein the activation of Rev-Erb has therapeutic effects, for instance in inflammatory and circadian rhythm-related disorders or cardiometabolic diseases. | 2017-10-19 |
20170296549 | PREVENTION OF ATHEROSCLEROTIC EVENTS WITH DIRECT FACTOR Xa INHIBITORS - The use of direct factor Xa inhibitors, administered in a dose sufficient to reduce the activity of factor Xa to about 25% less than normal or lower, has the effect of preventing the onset of atherosclerosis, and stabilizing atherosclerotic lesions, and preventing the occurrence or recurrence of atherosclerotic events. | 2017-10-19 |
20170296550 | ARYL SULTAM DERIVATIVES AS RORc MODULATORS - Compounds of the formula I: | 2017-10-19 |
20170296551 | COMBINATION OF AURORA KINASE INHIBITORS AND ANTI-CD20 ANTIBODIES - The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies. | 2017-10-19 |
20170296552 | TRANSDERMAL DELIVERY OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE - The invention discloses solutions of diclofenac, carbamazepine and benzydamine, at therapeutically desirable concentrations and the solutions stable for extended periods of time at room temperature. | 2017-10-19 |
20170296553 | MOLYBDENUM COMPOUNDS FOR USE IN THE TREATMENT OF CYANIDE POISONING - The present invention relates to compositions comprising molybdenum compounds, novel molybdenum compounds, kits and methods for their preparation. In particular, the present invention relates to compositions comprising molybdenum compounds for use in the treatment of cyanide poisoning in mammals, in particular humans. | 2017-10-19 |
20170296554 | ANTIMICROBIAL COMPOSITIONS AND METHODS OF MAKING THE SAME - The present disclosure comprises antimicrobial compositions and devices comprising silver compounds that resist heat and light discoloration. In one aspect, the said compounds comprise silver and at least one s-triazine ring or moiety. In another aspect, the antimicrobial compositions are hydrogels that are effective against broad spectrum of common pathogens including MRSA and VRE and are suitable for treating human or animal wounds and burns. The methods of the present disclosure comprise treating medical and non-medical devices and articles with compositions comprising the silver compounds to impart antimicrobial property. | 2017-10-19 |
20170296555 | TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE - The present invention concerns protection of an organ or tissue outside of the central nervous system following an ischemic episode. In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth. In specific embodiments, the organ is subjected to an inhibitor of an NC | 2017-10-19 |
20170296556 | METHODS OF TREATING CANCER - The present invention relates to methods of treating or preventing cancer in a subject in need thereof comprising administering a therapeutically effective amount of a compound of the invention. | 2017-10-19 |
20170296557 | Methods and Compositions for Treating Psoriasis - Method and composition for treating psoriasis and other skin disorders. | 2017-10-19 |
20170296558 | USE OF 2AMD AND 2MD TO TREAT FIBROSIS - The invention relates to using 2-methylene-19-nor-(20S)-1α,25-(OH) | 2017-10-19 |
20170296559 | MATERIALS AND METHODS FOR TREATMENT AND DIAGNOSIS OF DISORDERS ASSOCIATED WITH OXIDATIVE STRESS - The subject invention pertains to materials and methods for the prevention and treatment of disease conditions associated with oxidative stress or a compromised reducing environment, including inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. Another aspect of the subject invention concerns compositions formulated for administration as an enema. In one embodiment, a composition suitable for administration as an enema comprises an effective amount of 5-ASA and a steroid such as budesonide or hydrocortisone. The subject invention also concerns compositions formulated for oral administration. In one embodiment, a composition comprises alpha-lipoic acid, and/or N-acetyl-L-cysteine (N-A-C), and/or L-glutamine. The alpha-lipoic acid can be racemic alpha-lipoic acid, R-lipoic acid, or R-dihydro-lipoic acid. Methods of the invention include administration of compounds or compositions of the invention. In one embodiment, compounds or compositions of the invention are rectally instilled in a patient. In another embodiment, compounds or compositions are orally administered. The subject invention also concerns methods for screening for, assessing risk of developing, and/or diagnosing conditions associated with oxidative stress, such as ulcerative colitis and other inflammatory bowel disorders. | 2017-10-19 |
20170296560 | 2-AMINOETHANOL DIHYDROGEN PHOSPHATE-BASED DIETARY SUPPLEMENT AND SYNTHESIS PROCESS THEREOF - This invention discloses a process for creating an amino acid-based vitamin and mineral dietary supplement and muscle builder having therapeutic activities such as an antioxidant and a metabolic regulator, a regulator of possible cell dysfunctions, an adjuvant of human vitality and well-being and reduction of pain caused by different diseases wherein 2-aminoetanol dihydrogen phosphate is synthesized from phosphorus pentoxide and/or phosphoric acid and/or orthophosphoric acid reacted as monoethanolamine and/or diethanolamine and/or triethanolamine. These are reacted under optimal temperature conditions (−10 to +35° C.) at the specific molar ratios for each reagent used. | 2017-10-19 |
20170296561 | TREATMENT OF RETT SYNDROME - The present invention relates to agents and methods for treating autism spectrum disorders, such as Rett Syndrome. This invention addresses the need mentioned above by providing agents and methods for treating or ameliorating symptoms of neurologic diseases, such as autism spectrum disorders and Rett Syndrome. In one aspect, the invention provides a method for treating a neurologic disease associated with one or more mutations in the MECP2 gene. | 2017-10-19 |
20170296562 | FORMULATIONS OF AMINOGLYCOSIDES AND FOSFOMYCIN IN A COMBINATION HAVING IMPROVED CHEMICAL PROPERTIES - The present invention is synergistic antibiotic compositions having pH adjusted profiles for manufacturing combination, and administration, particularly for patients at risk or suffering from ventilator-associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis. Antibiotic compositions containing fosfomycin and aminoglycosides having individually predetermined and selected pH ranges are manufactured and stored for in combination prior to aerosolization, preferably with a specially designed in-line nebulizer attached to a ventilator. | 2017-10-19 |
20170296563 | IMMUNE SYSTEM STIMULATING NUTRITION - Disclosed is a nutritional composition comprising a combination of non-digestible oligosaccharides and a product obtained by incubating an aqueous substrate by bifidobacteria and optionally a product obtained by incubating an aqueous substrate by | 2017-10-19 |
20170296564 | USE OF NICOTINAMIDE RIBOSIDE, NICOTINIC ACID RIBOSIDE, AND NICOTINAMIDE MONONUCLEOTIDE, REDUCED NICOTINYL COMPOUNDS, AND NICOTINOYL COMPOUND DERIVATIVES IN INFANT FORMULA FOR HEALTHY DEVELOPMENT - Methods for delivering at least one compound selected from nicotinamide riboside (NR), nicotinic acid riboside (NAR), and nicotinamide mononucleotide (NMN), derivatives thereof, or salts thereof, in combination with at least one of thiamine (vitamin B1), riboflavin (vitamin B2), niacin (vitamin B3), and pyridoxine (vitamin B6), to an infant human subject in need of said compound or compounds are provided. | 2017-10-19 |
20170296565 | MOUSE MODEL AND TREATMENT OF HEREDITARY INCLUSION BODY MYOPATHY - Disclosed herein are methods of treating HIBM in a subject comprising identifying subject in need thereof; and administering to the subject a compound, or a pharmaceutically acceptable salt, ester, amide, glycol, peptidyl, or prodrug thereof, wherein the compound is a compound that is biosynthesized in a wild type individual along a biochemical pathway between glucose and sialic acid, inclusive. Also disclosed herein are vectors comprising a nucleic acid sequence that encodes a polypeptide having at least 80% sequence identity to the sequence set forth in SEQ ID NO:2, recombinant cells comprising these vectors, and recombinant animals comprising the cells. In addition, methods of identifying a compound having therapeutic effect for HIBM are disclosed. | 2017-10-19 |
20170296566 | METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS - Methods for treating and/or preventing mucositis comprising administering to a subject in need thereof an effective amount of at least one compound chosen from E-selectin antagonists, pharmaceutically acceptable salts of E-selectin antagonists, prodrugs of E-selectin antagonists, and pharmaceutically acceptable salts of prodrugs of E-selectin antagonists, and compositions comprising at least one of such compound. | 2017-10-19 |
20170296567 | Decubitus Ulcer Salve - A medical salve designed to address and treat bedsore, also known as decubitus ulcers. The medical salve includes a plurality of ingredients that each has their own unique beneficial properties. The plurality of ingredients includes a quantity of antibiotic powder composition, a quantity of antifungal powder, a quantity of topical steroid powder, a quantity of ethoxydiglycol, a quantity of silver sulfadiazine cream, a quantity of retinoic acid powder, a quantity of dimethyl sulfoxide solution, and a quantity of oleo plasticized base. The antibiotic powder composition, the antifungal powder, the topical steroid powder, the dimethyl sulfoxide solution, and the retinoic acid are the main active ingredients in the medical salve that are designed to address the symptoms of bedsores as well as expedite the healing process. The silver sulfadiazine cream, the ethoxydiglycol, and the oleo plasticized base are used as the base materials for medical salve. | 2017-10-19 |
20170296568 | SIRTUIN GENE POTENTIATOR, AND PHARMACEUTICAL PRODUCT, COSMETIC PRODUCT, AND FOOD PRODUCT USING SAME - Disclosed are a method for potentiating a sirtuin gene in a living body, provided to the living body as a pharmaceutical product, a cosmetic product, or a food product including a sirtuin gene potentiator. The sirtuin gene potentiator of the present invention contains a given polyphenol and/or terpenoid as an active component. The polyphenol and/or the terpenoid can be contained in the form of a plant such as pomegranate or a plant extract thereof. The sirtuin gene potentiator of the present invention is available from a familiar material to avoid concerns such as side effects on the human body in advance. Such a sirtuin gene potentiator is useful as a novel material in the fields of pharmaceutical products, cosmetic products, and food products. | 2017-10-19 |
20170296569 | ANTITUMOR ACTIVITY OF MULTI-KINASE INHIBITORS IN COLORECTAL CANCER - A composition for use in the prevention and/or treatment of colorectal cancer in a patient, comprising:
| 2017-10-19 |
20170296570 | High Drug Load Tablets Comprising Sofosbuvir - A tablet comprising a polymorphic form of crystalline sofosbuvir having a moisture stability of at least 95% in an amount of at least 40 weight-%. | 2017-10-19 |
20170296571 | METHODS AND COMPOSITIONS FOR WOUND HEALING - Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair. | 2017-10-19 |
20170296572 | Hydroxypropyl Beta-Cyclodextrin Compositions and Methods - This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C. | 2017-10-19 |
20170296573 | ANTITUMOR DRUG COMPRISING BETA-CYCLODEXTRIN - The present invention relates to an antitumor drug comprising β-cyclodextrin or a derivative thereof. In addition, the present invention relates to β-cyclodextrin characterized by the combination use with another antitumor drug, an antitumor drug comprising the combination, a combination therapy with β-cyclodextrin and another antitumor drug for treating cancer or the like, etc. | 2017-10-19 |
20170296574 | Method of Treating Inflammation - The present invention concerns methods of treating systemic, regional, or local inflammation from a patient suffering or at risk of inflammation comprising administration of a therapeutically effective dose of a sorbent that sorbs an inflammatory mediator in said patient. In some preferred embodiments, the sorbent is a biocompatible organic polymer. | 2017-10-19 |
20170296575 | FORMULATIONS COMPRISING POLYETHYLENE GLYCOL - The present invention concerns a solid formulation for oral administration as a solid comprising polyethylene glycol and a further solid such as mannitol. The formulation may be used to prevent gastrointestinal disorders such as constipation in healthy subjects. In some embodiments, the solid formulation is chewable or suckable. | 2017-10-19 |
20170296576 | Method for treating cervical intraepithelial neoplasia using poly-gamma- glutamic acid - The present invention is directed to a method of treating cervical intraepithelial neoplasia by administering a composition containing poly-gamma-glutamic acid. According to the present invention, cervical intraepithelial neoplasia in unmarried women, pre-childbirth women, or women who do not want infertility, can be treated without concern about infertility. | 2017-10-19 |
20170296577 | Multi-dose Compositions Containing an Antimicrobial Polyamide or Octenidine Preservative - The present invention relates to non-mercurial preservatives, including antimicrobial polyamide polymers and octenidine, and to methods of use thereof to produce preservative-containing multi-dose formulations. The preservative-containing multi-dose formulations exhibit resistance to one or more contaminating microorganisms, and have advantageous properties with respect to long term stability of biological and small molecule active ingredients. | 2017-10-19 |
20170296578 | TREATMENT OF CANCER WITH HYPOCHLOROUS ACID - The present invention relates to hypochlorous acid compositions and their use in therapy for cancer patients. | 2017-10-19 |
20170296579 | HEMOSTATIC COMPOSITIONS, DEVICES, AND METHODS - Compositions that include a clay such as kaolin dispersed in a liquid such as water may be useful for promoting the clotting of blood. The compositions may be in a liquid, gel, paste, foam, or another form. Uses may include treating a traumatic injury such as in injury caused by a bullet, an explosive, a blade etc., or an injury caused during a medical procedure such as surgery. | 2017-10-19 |
20170296580 | APYROGENIC PREPARATION CONTAINING NANOPARTICLES SYNTHESISED BY MAGNETOTACTIC BACTERIA FOR MEDICAL OR COSMETIC APPLICATIONS - A non-pyrogenic preparation containing nanoparticles synthesized by magnetotactic bacteria for medical or cosmetic applications. The nanoparticles are constituted by a crystallized mineral central part including predominantly an iron oxide, as well as a surrounding coating without material from the magnetotactic bacteria. | 2017-10-19 |
20170296581 | BONE MATRIX COMPOSITIONS AND METHODS - Osteoinductive compositions and implants having increased biological activities, and methods for their production, are provided. The biological activities that may be increased include, but are not limited to, bone forming; bone healing; osteoinductive activity, osteogenic activity, chondrogenic activity, wound healing activity, neurogenic activity, contraction-inducing activity, mitosis-inducing activity, differentiation-inducing activity, chemotactic activity, angiogenic or vasculogenic activity, and exocytosis or endocytosis-inducing activity. In one embodiment, a method for producing an osteoinductive composition comprises providing partially demineralized bone, treating the partially demineralized bone to disrupt the collagen structure of the bone. In another embodiment, an implantable osteoinductive and osteoconductive composition comprises partially demineralized bone, wherein the collagen structure of the bone has been disrupted, and, optionally, a tissue-derived extract. | 2017-10-19 |
20170296582 | METHOD FOR PROLIFERATING NEURAL PROGENITOR CELLS AND COMPOSITION FOR TREATING NEUROLOGICAL DISEASES CONTAINING PROLIFERATED NEURAL PROGENITOR CELLS - The present invention provides a method for proliferating neural progenitor cells and a composition for treating neurological diseases, the composition including a proliferated neural progenitor cell. When a fetal neural progenitor cell is cultured under a hypoxia condition and/or in a medium containing tocoperol, tocoperol acetate, or a mixture thereof, the improved cell proliferation rates of the fetal neural progenitor cell are confirmed. In addition, considering an effect of the neural progenitor cell on preventing differentiation thereof into neurons at the time of proliferation, the present disclosure may contribute to mass production of neural stem cells, and accordingly, the proliferated neural progenitor cell is expected to be utilized in the treatment of a neurological disease. | 2017-10-19 |
20170296583 | METHOD AND COMPOSITION FOR PRODUCING ENHANCED ANTI-INFLAMMATORY/ ANTI-CATABOLIC AND REGENERATIVE AGENTS FROM AUTOLOGOUS PHYSIOLOGICAL FLUID - Described are methods of producing an autologous composition useful for treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal. The method comprises preparing an anti-inflammatory/anti-catabolic component of the autologous composition comprising IL-1ra and TIMPs. An anti-inflammatory/anti-catabolic component is prepared comprising: collecting blood from the mammal; delivering the blood to a tube; incubating the blood at a temperature of from about 37° C. to about 39° C. for about 24 hours, preferably in the presence of sodium citrate; centrifuging the blood to separate the blood into a supernatant component and a cellular fraction; and collecting the supernatant component. The method further comprises preparing a regenerative component of the autologous composition comprising: collecting blood from the mammal; delivering the blood to a tube in the presence of about 4% citric acid; centrifuging the blood to separate a platelet-rich plasma component from a whole blood; collecting the platelet-rich plasma component; and mixing the supernatant component with the platelet-rich plasma component to provide the autologous composition. Also provided is a method of treating damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a subject with the autologous composition, an autologous composition for treating damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal and the use of the autologous composition for the treatment of damaged and/or injured connective tissues, chronic tendinosis, chronic muscle tears and/or chronic degenerative joint conditions and skin inflammatory disorders in a mammal. | 2017-10-19 |
20170296584 | METHODS FOR EXPANDING T CELL POPULATIONS - The present invention provides methods for expanding populations of T cell. The present invention further provides pharmaceutical compositions comprising the expanded T cells, including, γδ T cells, and use thereof for treating infectious, autoimmune or malignant diseases. | 2017-10-19 |
20170296585 | IDENTIFICATION AND ISOLATION OF MULTIPOTENT CELLS FROM NON-OSTEOCHONDRAL MESENCHYMAL TISSUE - Identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. This invention relates to the identification and isolation of multipotent cells from non-osteochondral mesenchymal tissue. Specifically, it relates to an adult multipotent cell or a cell population or composition comprising said cell, isolated from non-osteochondral mesenchymal tissue, characterized in that it is positive for the following markers: CD9, CD10, CD13, CD29, CD44, CD49A, CD51, CD54, CD55, CD58, CD59, CD90 and CD105 and because it lacks expression of the following markers: CD11b, CD14, CD15, CD16, CD31, CD34, CD45, CD49f, CD102, CD104, CD106 and CD133. | 2017-10-19 |
20170296586 | PHARMACEUTICAL COMPOSITION FOR TREATING CEREBRAL ATROPHY ASSOCIATED DISEASE - The present invention provides a pharmaceutical composition to treat cerebral atrophy associated disease. Said pharmaceutical composition comprising adipose-derived stem cells, can reverse the function of excitatory synapses in dementia patients and improve the function of memory storage area in brain. | 2017-10-19 |
20170296587 | STEM CELL THERAPY OF NEUROLOGICAL MANIFESTATIONS OF A VIRAL INFECTION - Disclosed are compositions of matter, protocols, and methods of treatment of neurological manifestations using stem cells, stem cell stimulators, and combination treatments. In one embodiment, a patient suffering neurological manifestations of a viral infection is administered a therapeutically active dose(s) of mesenchymal stem cells at a frequency and concentration sufficient to induce amelioration, remission or cure of neurological manifestations. | 2017-10-19 |
20170296588 | MESENCHYMAL STEM CELLS DERIVED FROM PLACENTAL SOURCES - Disclosed cell therapeutics useful for regenerative, immune modulatory and angiogenic applications. In one embodiment the invention teaches uses of placentally derived cells possessing mesenchymal features, said cells obtained by enriching for a subpopulation of cells in which said subpopulation expresses a CD45 negative phenotypic profile and further enriching for cells that express which express a CD34. Said cells may be modified by culture in conditions that enhance regenerative, immunological, or angiogenic activities. | 2017-10-19 |
20170296589 | COMPOSITIONS AND METHODS FOR TREATING LUNG REMODELING DISEASES - In one aspect, the present disclosure can relate to a method for treating a lung remodeling disease in a subject. One step of the method can include assaying one or more mesenchymal stem cells (MSCs) for one or more of the following effects: (1) reduce collagen deposition in the lungs of the subject; (2) increase expression of a transcription factor in an alveolar macrophage of the subject; (3) decrease expression of a cytokine in an alveolar macrophage of the subject; (4) decrease expression of a toll-like receptor (TLR) in an alveolar macrophage of the subject; (5) decrease mRNA synthesis of collagen 1 and/or collagen 3 in the subject; and (6) decrease the level of hyaluronic acid in the subject. A therapeutically effective amount of the one or more assayed MSCs found to have one or more of effects (1)-(6) can then be administered to the subject. | 2017-10-19 |
20170296590 | COMPOSITION FOR INDUCING CHONDROCYTE DIFFERENTIATION AND REGENERATING CARTILAGE TISSUE - A composition, for inducing chondrocyte differentiation or regenerating cartilage tissue or both, includes exosomes derived from stem cells differentiating into chondrocytes. | 2017-10-19 |
20170296591 | CARDIOSPHERE-DERIVED CELLS (CDCS) AS THERAPEUTIC AGENTS FOR PULMONARY HYPERTENSION - Described herein are compositions and techniques for treatment of disease and conditions such as pulmonary arterial hypertension (PAH). Unlike palliative or preventive measures that do not address the abnormal vasculature causing onset of right ventricular compensation the use of stem cell-based therapy can directly impact the microvascular pathology in PAH, thereby reversing the course of the disease. | 2017-10-19 |
20170296592 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES - The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues. | 2017-10-19 |
20170296593 | CELL POPULATIONS HAVING IMMUNOREGULATORY ACTIVITY, METHOD FOR ISOLATION AND USES - The present invention provides a population of connective tissue derived cells that respond to interferon-gamma (IFN-γ) by expressing indolamine-2,3-dioxygenase (IDO) for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to, autoimmune diseases, inflammatory disorders, and immunologically mediated diseases including rejection of transplanted organs and tissues. | 2017-10-19 |
20170296594 | DIFFERENTIATION OF PLURIPOTENT STEM CELLS TO INTESTINAL MIDGUT ENDODERM CELLS - Cell populations of intestinal midgut endoderm cells and methods of generating the cells expressing markers characteristic of intestinal endoderm lineage are disclosed. Methods of treating conditions such as diabetes are also disclosed. | 2017-10-19 |
20170296595 | Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof - This invention relates generally to the discovery of novel mammalian lung spheroids and lung spheroid cells and uses thereof. | 2017-10-19 |
20170296596 | METHOD FOR TREATMENT OF DISORDERS OF THE GASTROINTESTINAL SYSTEM - There are provided novel synthetic stool preparations comprising bacteria isolated from a fecal sample from a healthy donor. The synthetic stool preparations are used for treating disorders of the gastrointestinal tract, including dysbiosis, | 2017-10-19 |
20170296597 | MICROBIOTA RESTORATION THERAPY (MRT), COMPOSITIONS AND METHODS OF MANUFACTURE - Microbiota restoration therapy compositions and methods for manufacturing, processing, and/or delivering microbiota restoration therapy compositions are disclosed. An example method may include a method of treating an infection. The method may comprise administering a microbiota restoration therapy composition to a patient with an infection. The microbiota restoration therapy composition may comprise a mixture of an effective amount of fecal microbiota and an effective amount of polyethylene glycol. | 2017-10-19 |
20170296598 | METHOD OF PREPARING STABLE, WATER SOLUBLE PROBIOTIC COMPOSITIONS BASED ON MILLETS AND SIMILAR CEREALS - The probiotic powder compositions comprising probiotic microorganisms encapsulated in nutritional rich cereal powder matrix. Encapsulation of probiotics in cereal powders offers nutritive and health benefits to the consumer. The present invention further includes methods of making and using the probiotic powder compositions of the invention. The powder compositions are stable, maintains the viability of probiotic microorganisms in various formulations. | 2017-10-19 |
20170296599 | Materials and Methods for Improving Immune Responses and Skin and/or Mucosal Barrier Functions - The subject invention provides compositions and methods for treating human dermatological conditions by employing a microbiome-centered treatment approach. Preferred embodiments of the invention provide pharmaceutical and cosmetic compositions, and the methods of using the same, comprising a strain of | 2017-10-19 |
20170296600 | Probiotic Stabilization - An ingestible composition including a probiotic contained in a mixture of hydrolyzed mammalian protein, one or more carbohydrates and a compound binder useful for nutrition of infants and children. | 2017-10-19 |
20170296601 | Compositions and Methods for Treating an Immunodeficiency Virus Infection - The present disclosure provides an interfering, conditionally replicating human immunodeficiency virus (HIV) construct; infectious particles comprising the constructs; and compositions comprising the construct or the particle. The constructs, particles, and compositions are useful in methods of reducing HIV viral load in an individual, which methods are also provided. | 2017-10-19 |
20170296602 | Beneficial Growth and Constituents of Mushrooms on Substrate Containing Cannabis Plant Material - The present invention is a method of wowing mushrooms, preferably but not necessarily) Basiomycetes mushrooms, on a substrate that includes unrefined, live or dried cannabis plants (whole or particulated) preferably those cannabis, strains high in CBD and low in THC or containing a preferred ratio thereof, as part or all of the growth medium for the mushrooms. | 2017-10-19 |
20170296603 | USES OF FU-LING (PORIA COCOS) EXTRACT AND TUMULOSIC ACID IN PROTECTING MUSCLES - A method for protecting muscles, comprising administering to a subject in need an effective amount of a FU-LING (Poria cocos) extract, tumulosic acid and/or a pharmaceutical acceptable salt of tumulosic acid. In particular, the method of the present invention is for protecting muscle cells against injury, promoting regeneration and repair of muscle, regulating, treating and/or delaying muscle atrophy (especially caused by aging, diseases, and cachexia), or helping normal muscle contraction, maintaining normal muscle physiology, maintaining normal neuromuscular function, maintaining normal energy metabolism, or enhancing energy level. | 2017-10-19 |
20170296604 | COMPOSITION FOR PREVENTING OR ALLEVIATING PERIODONTAL DISEASES, CONTAINING, AS ACTIVE INGREDIENT, MANGOSTEEN EXTRACT OR ALPHA- OR GAMMA- MANGOSTEEN - The present invention provides a composition for preventing, improving or treating periodontal diseases comprising extract of mangosteen. | 2017-10-19 |
20170296605 | COMPOSITIONS AND METHODS FOR IMPROVED MUSCLE METABOLISM - A composition for improving muscle metabolism in a subject and methods for manufacturing and using same. Embodiments include compositions having an extract of | 2017-10-19 |
20170296606 | 331 NEW FOUND PROTEINS IN PEANUT WITH THEIR SEQUENCE AND THE METHOD OF PRODUCING SUPPLEMENT INCLUDING BEVERAGES ON THE BASIS OF JUICE AND POWDER FROM THE PEANUT - 331 new found proteins in peanut with their sequence and the method of producing supplement including beverages on the basis of juice and powder from the peanut. 490 new found proteins in cashew sequence and method of producing food supplements including beverages on the basis of juice and powder from the cashew. 843 new found proteins in edamame (young soy) sequence and method of producing food supplement including beverages on the basis of juice and powder from the edamame (young soy) | 2017-10-19 |
20170296607 | COMPOSITION INCLUDING EXTRACT OF DOLICHOS LABLAB LINNE AS ACTIVE INGREDIENT FOR PREVENTING OR AMELIORATING NON-ALCOHOLIC FATTY LIVER DISEASE - A health functional food composition and a pharmaceutical composition for preventing or ameliorating a non-alcoholic fatty liver disease include an extract of | 2017-10-19 |
20170296608 | COMPOSITION OF DECREASING THE ACCUMULATION OF FAT AND USE THEREOF - The present invention provides a natural composition of reducing weight gains and decreasing the accumulation of fat, comprising | 2017-10-19 |
20170296609 | COMPOSITIONS AND METHODS FOR MAINTAINING OR ENHANCING HOMEOSTASIS OR FUNCTION OF FEMALE LOWER REPRODUCTIVE TRACT - The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a | 2017-10-19 |
20170296610 | COMPOSITIONS AND METHODS FOR MAINTAINING OR ENHANCING HOMEOSTASIS OR FUNCTION OF FEMALE LOWER REPRODUCTIVE TRACT - The present disclosure provides compositions and methods for making and using topical compositions comprised of an isotonic, biome-friendly solution containing xylose and/or a | 2017-10-19 |
20170296611 | Pharmaceutical Compositions Comprising Extracts of Sarcopoterium Spinosum, Components Thereof, and Uses Thereof - Disclosed are pharmaceutical compositions comprising extracts of | 2017-10-19 |
20170296613 | DERMATOLOGICAL KIT COMPRISING COMPOSITIONS BASED ON HIBISCUS FLOWER AND BURITI OIL - The invention provides a dermatological kit comprising a first container comprising a first composition and a second container comprising a second composition, different from the first composition, wherein the first composition comprises trichloro-acetic acid and a hibiscus acid, wherein the second composition comprises a material of | 2017-10-19 |
20170296614 | Herbal Extract Composition - The present invention relates to the field of herbal compositions. In particular, the present invention is directed to an Improved Herbal Extract Composition comprising a Melissa species extract, an Avena species extract, a Tilia species extract and a unique blend of citrus components. The composition can further comprise at least one additional extract of a plant such as Citrus species, Crataegus species, Panax species, and Lavendula species. The herbal extract composition is useful in numerous ingestible forms including an extract concentrate for food and beverage preparation, additive or enhancer for existing foods and beverages and particularly in the form of a pleasant tasting and soothing beverage. | 2017-10-19 |
20170296615 | METHOD AND COMPOSITION FOR A PROTEIN TRANSDUCTION TECHNOLOGY AND ITS APPLICATIONS - A protein transduction method for efficiently delivery of exogenous proteins into mammalian cells is invented, which has the capability of targeting different cellular compartments and protection from degradation of the delivered proteins from cellular proteases. A composition for treat proteins has cation reagents, lipids and enhancers in a carrier. The method can be used in a number of ways including: production of large quantities of properly folded, post-translationally modified proteins using mammalian cell machinery, a in-cell fluorescence spectroscopy and imaging using small molecule fluorophores and a in-cell NMR spectroscopy using living mammalian cells. The method permits cell biology at atomic resolution that is physiologically and pathological relevant and permits protein therapy to treat human diseases. The method can also be used to deliver exogenous protein inside mammalian cells, wherein the exogenous proteins follow a similar secretion pathway as that of the endogenous protein. | 2017-10-19 |
20170296616 | METHODS OF TREATING DEPRESSION USING NMDA MODULATORS - This disclosure provides methods and regimens for treating depression (e.g., treatment-resistant depression) in a patient (e.g., a patient n need of such treatment). | 2017-10-19 |
20170296617 | RHO ASSOCIATED KINASE (ROCK) INHIBITORS AND THEIR USE IN TREATING DISEASE - The present disclosure describes peptide inhibitors of Rho-associtated-kinase (ROCK) and their use in treating disorders including heart failure, the leading cause of combined morbidity and mortality in the United States. An inhibitory polypeptide blocks ROCK1 activity in the presence of 1 mM ATP. The binding epitope on ROCK1 was mapped using chemical cross-linking to the Activation Loop, a novel locus identifying a new class of inhibitory drugs. The peptides described will be useful against a number of important diseases such as heart disease, pulmonary hypertension, arterial hypertension, gluacoma management, insulin resistance, kidney disease, hemolytic anemia, stroke, ischemia reperfusion injury, or acute mycloid leukemia. | 2017-10-19 |
20170296618 | BRAIN PERMEANT PEPTIDOMIMETIC BETA-SECRETASE 1 INHIBITORS FOR THE TREATMENT OR PROPHYLAXIS OF NEUROLOGICAL DISORDERS OR CONDITIONS - The present application presents novel peptidomimetic substituted hydroxyethylene compounds, which are inhibitors of beta amyloid cleavage enzyme, capable to permeate the brain and to achieve therapeutic concentrations in the target organ, the brain. These compounds are incorporated in pharmaceutical compositions and applied in the treatment or prophylaxis of neurological disorders or conditions and also other disorders or conditions including Down's syndrome and diabetes. | 2017-10-19 |